Business
Lung Cancer Detection Strategic Alliance in China
Lung Cancer Detection Strategic Alliance in China.
About this update from Cizzle Biotechnology Holdings Plc
[{"type":"text","content":"\n \n \n \n RNS Number : 5195T\n Cizzle Biotechnology Holdings PLC\n 25 November 2021\n \n \n \n \n 25 November 2021\n \n \n Cizzle Biotechnology Holdings Plc\n \n \n \n \n \n (\"Cizzle Biotechnology\" or the \"Company\")\n \n \n \n \n \n Strategic Alliance for Early Lung Cancer Detection in China\n \n \n \n \n \n Cizzle Biotechnology, the UK based diagnostics developer, is pleased to announce that it has executed a Memorandum of Understanding (\"MOU\") with the International Co-Innovation Centre for Advanced Medical Technology (\"iCCAMT\") and Shenzhen Intelliphecy Life Technologies Co., Ltd. (\"Intelliphecy\") to develop and market the Company's proprietary early lung cancer diagnostic tests based on the CIZ1B cancer biomarker in China. \n \n \n Lung cancer is a major public health problem worldwide and especially in China, where it is still the most common diagnosed cancer and the leading cause of cancer related deaths. Early detection is essential in enabling early therapeutic intervention and improved outcomes. \n \n \n iCCMAT, founded with German Medical Valley, Robert Bosch GmbH and Sinopharm Group, aims to accelerate global med-tech innovation in the Chinese market, by bringing together world leading expertise. The strategic alliance is intended to accelerate product development and clinical trials to achieve early adoption within major cancer centers throughout China. \n \n \n The MOU is non-binding, but it is intended that a full commercial contract will be entered into in due course whereby the parties will collaborate closely in end-to-end development, manufacture and sale of early cancer detection products and services. The MOU envisages that iCCAMT and Intelliphecy will fund the activities in China and Cizzle Biotechnology will receive payment for monoclonal antibodies\n and reagents produced, and services provided, together with royalties on any sales of products and services in China.\n \n \n Initial pilots of Cizzle Biotechnology's lung cancer diagnostic tests are planned at the Cancer Hospital Chinese Academy of Medical Sciences, National Cancer Centre and Beijing Cancer Hospital affiliated with Peking University.\n \n \n Commenting, Allan Syms, Executive Chairman of Cizzle Biotechnology, said: \n \n \n \"We are delighted to establish this important collaboration to bring our simple bloo...